We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A cohort of patients treated with cell therapy showed ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

Please provide your email address to receive an email when new articles are posted on . A study presented at Angiogenesis, Exudation, and Degeneration 2024 provided insights on how geographic atrophy ...

All nine subjects of Phase 1 injected without any serious adverse events. Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today ...